Cipla Launches Authorized Generic of Aloxi
Cipla USA, Inc. has announced the launch of an authorized generic version of Aloxi in the US under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.
Aloxi – palonosetron hydrochloride injections (0.25 mg base/5 ml) – is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Helsinn Healthcare SA currently manufactures and markets Aloxi in the US through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. According to IMS Health, the brand had U.S. sales of approximately $460-mn for the 12-month period ending November 2017.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-09-01
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
A Cold-Chain Crackdown in Delhi Sends a Much Bigger Message
-
Biochem to Acquire BASF’s Global Glycinates Business
-
Soybeans Tread Water Amid Trade Whispers and Biofuel Hopes
-
Wanhua Chemical Is Fighting Counterfeits While Raising Prices
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
COSMAX Acquires 51% Stake in Keminova, Establishes First European Production Base
-
Lier Chemical Gains Momentum as Chlorantraniliprole Supply Stabilizes
Recommend Reading
-
![IFF to Establish Scent Creative Center in Mumbai]()
IFF to Establish Scent Creative Center in Mumbai
-
![AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value]()
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
![Tinergy Chemical Invests 11 Billion Yuan, Phosphate Iron Becomes New Strategic Focus]()
Tinergy Chemical Invests 11 Billion Yuan, Phosphate Iron Becomes New Strategic Focus
-
![China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million]()
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
-
![Toray to Transfer Stake in Soda Aromatic to Samyang]()
Toray to Transfer Stake in Soda Aromatic to Samyang
-
![Business Society’s August 17, 2026 View on Isooctanol Market Trends: Deep Correction Points to a Bearish Outlook]()
Business Society’s August 17, 2026 View on Isooctanol Market Trends: Deep Correction Points to a Bearish Outlook
-
![This week, the styrene market fluctuated and fell (9.1-9.5) in China]()
This week, the styrene market fluctuated and fell (9.1-9.5) in China
-
![Business Society’s August 17, 2026 Melamine Market Outlook: Weak Rebound]()
Business Society’s August 17, 2026 Melamine Market Outlook: Weak Rebound
-
![This week, the cyclohexanone market in Shandong, China, has been consolidating]()
This week, the cyclohexanone market in Shandong, China, has been consolidating
-
![Business Society’s Market Outlook for Ethyl Acetate on August 17, 2026: Volatile]()
Business Society’s Market Outlook for Ethyl Acetate on August 17, 2026: Volatile
